Article
Preparation of functional liposomes with peptide ligands and their binding to cell membranes.
Biomolecules Department, National Institute of Bioscience and Human-Technology, Tsukuba, Ibaraki, Japan.
Lipids (impact factor:
2.13).
07/2000;
35(6):673-80.
DOI:10.1007/s11745-000-0572-4
pp.673-80
Source: PubMed
-
Citations (0)
- Cited In (1)
-
Article: Surface-Engineered Nanoliposomes by Chelating Ligands for Modulating the Neurotoxicity Associated with β-Amyloid Aggregates of Alzheimer's disease.
[show abstract] [hide abstract]
ABSTRACT: To develop chelating ligand-bound nanoliposomes (NLPs) for the prevention and reversal of β-Amyloid (Aβ) aggregation associated with promoting neurotoxicity in Alzheimer disease (AD). Four different chelating ligands (CuAc, EDTA, histidine and ZnAc) were surface-engineered onto NLPs using either covalent or non-covalent conjugation. Successful conjugation of chelating ligands onto the surface of NLPs was confirmed by characterization studies: SEM, TEM and FTIR analysis. Chelation energetics of EDTA with Cu(II)/Zn(II)-Aβ(10-21) and nanoformation of emulsified polymers were computed and corroborated with experimental and analytical data using chemometric molecular modeling. The modified NLPs produced were spherical in shape, 127-178 nm in size, with polydispersity index from 0.217-0.920 and zeta potential range of -9.59 to -37.3 mV. Conjugation efficiencies were 30-76 %, which confirmed that chelating ligands were attached to the NLP surface. In vitro and ex vivo results elucidated the effectiveness of chelating ligand-bound NLPs for prevention of CuAβ(1-42) or ZnAβ(1-42) aggregate buildup associated with neurotoxicity in PC12 neuronal cells, as well as promotion of intracellular uptake in the presence of Cu(II) or Zn(II) metal ions.Pharmaceutical Research 05/2012; 29(11):3075-89. · 4.09 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
alpha-MSH)] sequence
B16 cells
conventional methods
flow cytometry
freeze-thaw method
GRGDS
immunoelectron microscopy
liposome bearing
liposome bearing alpha-MSH peptide ligand binds
liposome membranes
liposomes bearing
NIH3T3 cells
novel lipopeptides
peptide ligands
peptide ligands [alpha-melanocyte stimulating hormone
present method
repeated GRGDS sequence binds
solid-phase method
surface-modified liposomes
synthesized